Fremman Capital has acquired a majority stake in DIESSE Diagnostica Senese, a prominent Italian company specializing in In Vitro Diagnostics (IVD). This transaction, conducted in partnership with ARCHIMED, allows DIESSE’s management team to retain a significant minority stake, ensuring their continued involvement in the company's growth.

Founded in 1980, DIESSE has established itself as a leader in the specialty IVD market, particularly in diagnostics for autoimmune and infectious diseases, as well as hematology measurement systems. The company boasts a comprehensive portfolio of over 170 specialty immunoassay tests, all available on fully automated instruments. DIESSE operates a fully integrated business model, managing everything from scientific research and development to instrument design and reagent production, which guarantees high-quality control.

Headquartered in Monteriggioni, Italy, DIESSE operates from the DIESSE Biotech Campus, the largest R&D and biotech production facility dedicated to IVD in Italy, employing around 230 people. Its products are distributed globally, serving clinical laboratories, hospitals, and private labs in over 100 countries.

The specialty diagnostics market is poised for significant growth, driven by factors such as increasing life expectancy, a rise in autoimmune diseases, and a higher frequency of testing. These trends align with Fremman’s investment strategy, which focuses on essential goods and services that promise long-term value in resilient sectors.

Massimiliano Boggetti, CEO of DIESSE, highlighted the company’s commitment to innovation, noting that over the past five years, they have invested more than 10% of their revenues into research and development. With Fremman’s support, DIESSE aims to expand its innovative diagnostic solutions globally, improving patient outcomes.

Edward Chandler, Founding Partner at Fremman, expressed enthusiasm about partnering with DIESSE’s management team, emphasizing the company’s strong position in the recession-resistant IVD market. He sees substantial opportunities for international expansion and enhancing DIESSE’s market leadership.

DIESSE is recognized for its innovative IVD solutions, catering to various medical needs, including autoimmunity and infectious diseases. The company’s products are utilized by clinical laboratories and hospitals worldwide, supported by a robust distribution network.

Fremman Capital is a pan-European investment firm focused on mid-market opportunities, with offices across major European cities. The firm collaborates with management teams to transform businesses into sustainable leaders, leveraging over a century of combined investment experience to foster growth that benefits society.

In summary, the acquisition of DIESSE by Fremman Capital marks a strategic move to enhance the company’s growth trajectory in the specialty IVD market, capitalizing on emerging global healthcare trends and innovations.